Please login to the form below

Not currently logged in

GSK to assist in manufacturing up to 60 million doses of Novavax’s COVID-19 vaccine in the UK

Vaccine candidate is expected to be submitted to UK regulatory authorities in Q2

GlaxoSmithKline (GSK) has signed an agreement to help make up to 60 million doses of Novavax’s COVID-19 vaccine NVX-CoV2373 in the UK.

The agreement between GSK, Novavax and the UK Vaccines Taskforce will see GSK provide fill and finish manufacturing capacity at its facility located in Barnard Castle, in the North East of England.

Although the parties need to negotiate a final agreement, technology transfer between GSK and Novavax is to begin immediately.

The UK government signed an advanced purchase agreement with Novavax in August 2020 for 60 million doses of NVX-CoV2373.

As part to the deal, Novavax conducted a phase 3 clinical trial of its vaccine candidate with support from the UK’s National Institute for Health Research (NIHR).

Novavax also partnered with FUJIFILM Diosynth Biotechnologies to manufacture certain components of the vaccine in the UK, including the protein antigen component.

In January, Novavax revealed the initial results from the UK trial of NVX-CoV2373 that showed the vaccine candidate had an overall efficacy rate of 89.3%, based on 62 PCR-confirmed, symptomatic COVID-19 cases.

Preliminary analysis also found that the UK variant was detected in over 50% of the PCR-confirmed cases, with 32 cases being caused by the UK variant, 24 by the non-variant and six ‘unknown’.

Based on this information, Novavax calculated that its vaccine is 95.6% effective against the original COVID-19 strain and 85.6% effective against the UK variant.

“GSK is delighted to support Novavax and the UK Vaccines Taskforce with this manufacturing arrangement for the UK and our Barnard Castle facility is now undertaking the rapid preparation work required to manufacture up to 60 million doses of this vaccine,” said Roger Connor, president of GSK Vaccines.

“We have ensured that we can deliver these volumes without impacting supply of our other vital medicines and vaccines, and without disruption to the other COVID-19 collaborations GSK is engaged in globally,” he added.

Novavax is expecting to submit its vaccine candidate for review by regulatory authorities in the UK during the second quarter of 2021.

Article by
Lucy Parsons

30th March 2021

From: Marketing



COVID-19 Updates and Daily News

Featured jobs


Add my company
Healthcare Media Europe – HME Ltd

HME are an innovative and technology enabled agency offering our clients over 35+ years of knowledge and expertise in delivering...

Latest intelligence

How innovating study sites can improve patient recruitment efficiency
There are so many ways that clinical trials have innovated over the last few years. There is now a larger focus on making trials more patient-centric, more virtualised, and more...
Avoiding A Series of Unfortunate Events: launch lessons from lockdown
Chris Ross takes a novel look at launch excellence through the lens of COVID-19 and explores how pharma’s launch leaders are rewriting the story...
6 reasons patients drop out of clinical trials and 6 ways to fix it
If you’ve successfully recruited patients for your clinical trial, but one by one, they begin to drop out, then this information could be for you....